Pre-Treatment Guidelines for Patients Undergoing Durvalumab and Tremelimumab Therapy at Lyon Civilian Hospices

news: A new Immunotherapy treatment combining Durvalumab and Trémélimab is being offered to patients with hepatocellular carcinoma, the most frequent type of liver cancer. Learn about potential side effects and the care pathway.">

News">

New Immunotherapy Option For Liver Cancer Patients Unveiled

Published: 2025-09-17

A novel Immunotherapy regimen utilizing Durvalumab and Trémélimab is now available for individuals diagnosed with hepatocellular carcinoma, commonly known as liver cancer. This treatment approach, detailed in a recent information notice, targets the most prevalent form of this disease and offers a new avenue of hope for patients.

Multidisciplinary Approach to Treatment Decisions

The selection of this treatment is not made in isolation. A collaborative process, involving a multidisciplinary consultation meeting (RCP), sees a team of medical specialists from various fields converge to determine the most suitable course of action for each individual case. This ensures a holistic and well-informed treatment plan.

Understanding the Immunotherapy Combination

This innovative treatment employs a dual-immunotherapy approach. Durvalumab, an anti-PDL-1 immunotherapy, works in conjunction with Trémélimab, an anti-CTLA4 immunotherapy, to stimulate the bodyS own immune system to fight the cancer. This combination seeks to enhance the immune response for improved treatment outcomes.

Potential Side Effects to Be Aware Of

As with any medical intervention, potential side effects are an important consideration. Patients undergoing this treatment may experience:

• Diarrhea
• Cirrhosis Decompensation
• Skin Rash
• Heart Toxicity
• Joint and Muscular pain, Cramps
• Endocrine Disorders
• Liver Function Disorders
• Renal Function Disorder
• Pulmonary Toxicity

Patients are encouraged to openly discuss any concerns or experiences with their healthcare team. Proactive management of these potential side effects is a crucial component of the treatment process.

The Two-Year Care Pathway and Day Hospital Experience

The treatment plan extends over a two-year period, and patients will benefit from structured support throughout.A typical day at the day hospital will be outlined to provide clarity and prepare individuals for their treatment sessions. Professional guidance and recommendations will be provided on an as-needed basis, adapting to individual circumstances.

Did You know? According to the American Cancer Society, approximately 42,810 new cases of liver cancer will be diagnosed in the United States in 2024, highlighting the urgent need for innovative treatment options.source: American Cancer Society

Pro Tip: Maintaining open communication with your medical team is paramount throughout your treatment journey. Don’t hesitate to ask questions or voice any concerns you may have.

Treatment Component	Type of Immunotherapy	Target
Durvalumab	Anti-PDL-1	PD-L1 protein, blocking cancer cells from evading the immune system
Trémélimab	Anti-CTLA4	CTLA-4 protein, enhancing the immune response by activating T cells

Understanding Liver Cancer: A Deeper Dive

Liver cancer, encompassing various types, arises when cells in the liver begin to grow uncontrollably. Hepatocellular carcinoma (HCC) is the most common type, accounting for the majority of primary liver cancers. Risk factors include chronic hepatitis infection, cirrhosis, excessive alcohol consumption, and obesity.Early detection and advanced treatment options are critical for improving patient outcomes. Learn more about liver cancer from the Mayo Clinic.

Frequently Asked Questions About This Immunotherapy Treatment

• What is liver cancer immunotherapy? Immunotherapy for liver cancer uses medications to help your immune system fight the cancer.
• What are the common side effects of Durvalumab and Trémélimab? Common side effects include diarrhea, skin rash, and fatigue, but more serious side effects are possible.
• How long does the treatment with durvalumab and Trémélimab last? This treatment is planned for a period of two years, with regular monitoring and follow-up.
• What is a multidisciplinary consultation meeting (RCP)? It’s a meeting where doctors from different specialties discuss the best treatment plan for a patient.
• Is this treatment suitable for all types of liver cancer? This treatment is specifically indicated for hepatocellular carcinoma, the most frequent form of liver cancer.

What are your thoughts on the advancements in immunotherapy for liver cancer? Share your insights in the comments below!

What is teh significance of an ECOG performance status score of 0-1 in determining a patient’s eligibility for Durvalumab and Tremelimumab therapy?

Initial Patient Evaluation & Eligibility Criteria

Before initiating treatment with Durvalumab and Tremelimumab at Lyon Civilian Hospices, a comprehensive pre-treatment evaluation is crucial. This ensures patient safety and optimizes treatment efficacy. Key components include:

* Performance Status Assessment: Utilizing the ECOG (Eastern Cooperative Oncology Group) performance status scale to gauge the patient’s functional ability. A score of 0-1 is generally preferred for optimal treatment tolerance.

* Complete Medical History: Detailed review of past medical conditions, including autoimmune diseases, pre-existing lung conditions (like COPD or interstitial lung disease), cardiovascular disease, and active infections. patients with a history of autoimmune disease require careful consideration and potential consultation with a rheumatologist.

* Medication Review: A thorough assessment of all current medications,including over-the-counter drugs and herbal supplements. Particular attention is paid to immunosuppressants (e.g., corticosteroids, methotrexate) as these may need adjustment or discontinuation.

* tumor Characteristics: Confirmation of appropriate biomarker expression (PD-L1 status) as indicated by the specific cancer type and treatment protocol.Detailed pathology reports are essential.

* Organ Function Tests: Baseline assessments of renal function (serum creatinine, eGFR), hepatic function (AST, ALT, bilirubin), and hematological parameters (complete blood count with differential).

Required Pre-Treatment Investigations

A standardized panel of investigations is mandatory prior to commencing Durvalumab and Tremelimumab therapy. These tests help establish a baseline and monitor for potential adverse events.

* Radiological Assessments:

* CT Scan (Chest, Abdomen, Pelvis): To assess disease burden and rule out active infections.

* MRI (Brain): Considered for patients with neurological symptoms or a history of brain metastases.

* Bone Scan: If clinically indicated, to evaluate for bone metastases.

* Laboratory Tests:

* Comprehensive Metabolic Panel (CMP): Assessing liver and kidney function.

* Complete Blood Count (CBC) with Differential: Monitoring for hematological toxicities.

* Thyroid Function Tests (TSH, Free T4): Immune checkpoint inhibitors can induce thyroid dysfunction.

* Autoantibody Panel: Including ANA (antinuclear antibody) and other relevant autoantibodies to screen for pre-existing autoimmune conditions.

* Viral Hepatitis Serology (HBV, HCV): To identify and manage potential viral reactivation.

* HIV Testing: Mandatory screening.

* Inflammatory Markers: CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate) can provide baseline data.

Management of Pre-Existing Conditions

Specific pre-existing conditions require tailored management strategies before initiating Durvalumab and Tremelimumab.

* Autoimmune Disease: Patients with a stable autoimmune disease, adequately controlled with immunosuppression, may be considered for treatment. However, close monitoring for flares is essential. Immunosuppression may need to be cautiously tapered or held, in consultation with a rheumatologist.

* Interstitial Lung Disease (ILD): ILD is a relative contraindication. Patients with a history of ILD require careful evaluation by a pulmonologist. Treatment may be deferred or avoided depending on the severity and stability of the ILD.

* Cardiovascular Disease: Patients with pre-existing cardiovascular disease should undergo a cardiology evaluation to assess their risk and optimize management.

* Active Infections: Treatment must be delayed until active infections are resolved. Prophylactic antibiotics or antivirals might potentially be considered in certain cases.

Patient Education & Counseling

Comprehensive patient education is paramount. Patients must understand the potential benefits and risks of Durvalumab and Tremelimumab therapy.

* potential Side Effects: Detailed discussion of common immune-related adverse events (irAEs), including colitis, pneumonitis, hepatitis, endocrinopathies, and dermatologic reactions. Patients should be instructed on how to recognize symptoms and promptly report them to the medical team.

* Importance of Adherence: Emphasize the importance of adhering to the prescribed treatment schedule and attending all scheduled follow-up appointments.

* Emergency Contact Information: Provide patients with clear instructions on how to contact the medical team in case of emergencies.

* irAE Management Plan: A written plan outlining the initial steps to take if irAEs develop. This includes contact information for the relevant specialists (e.g., gastroenterologist, pulmonologist, endocrinologist).

practical Tips for Pre-Treatment Preparation

* Medication Reconciliation: Bring a complete list of all medications to the initial consultation.

* Hydration: Maintain adequate hydration in the days leading up to treatment.

* Nutrition: Ensure a balanced diet to support overall health.

* Support System: Arrange for a support person to accompany the patient to appointments and provide assistance as needed.

* **Travel Considerations